The various prime-time genetic variants influencing cardiovascular drug responses discussed here include CYP2C19 polymorphisms affecting clopidogrel drug response, CYP2C9 and VKORC1 polymorphisms impacting warfarin dose, SLCO1B1 variants associated with statin-induced myopathy risk, and CYP2D6 polymorphisms influencing β-blocker metabolism, particularly for metoprolol. Here, CYP2C9 is linked to myopathy.